Though low cost cards might help ease the burden of superior drug costs in the short term, they do not deal with the systemic concerns driving up prescription costs during the U.S. Broader policy adjustments could deal with the basis triggers of mounting drug rates, including deficiency of transparency in pricing plus the purpose of intermediaries